Treatment With OpRegen Shows Improvement in Visual Acuity, Cell Persistence in Dry AMD


New data from cohort 4 showed outer retinal restoration following treatment with OpRegen.

New data from the phase 1 clinical trial examining OpRegen in patients with dry age-related macular degeneration (AMD) show that the subretinal cell therapy may help improve or maintain visual acuity in this patient population, according to a presentation made at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in Denver, Colorado May 1-4, 2022 and virtually May 11-12, 2022.

The findings, presented by Allen C. Ho, MD, director of retina research and attending surgeon at Wills Eye Hospital, also demonstrated good persistence of OpRegen transplanted cells via alterations in drusen appearance, subretinal pigmentation, and hyper-reflective areas. In addition, in patients whose atrophic areas were extensively covered by the cell suspension (4/12), signs of outer retinal restoration and reduction in geographic atrophy were observed compared with baseline imaging.

OpRegen has been generally well-tolerated with no unexpected adverse events.

In an interview with CGTLive, lead investigator Ho details the findings from this latest analysis and extrapolates the potential of this therapy in dry AMD.

Ho A, Banin E, Barak A, et al. Safety and Efficacy of a Phase 1/2a Clinical Trial of Transplanted Allogeneic Retinal Pigmented Epithelium (RPE, OpRegen) Cells in Advanced Dry Age-Related Macular Degeneration (AMD). Presented at: 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 1-4, 2022, Denver, CO; May 11-12, 2022, virtual.
Related Videos
Alexandra Gomez Arteaga, MD
Mitchel Horwitz, MD
Paul Harmatz, MD
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
N. Nora Bennani, MD
Heather Lau, MD, MS, the executive director of global clinical development at Ultragenyx Pharmaceutical
Peter A. Merkel, MD, MPH, the chief of the Division of Rheumatology and a professor of medicine and professor of epidemiology at Penn Medicine
Related Content
© 2024 MJH Life Sciences

All rights reserved.